Serving Our Partners
Capabilities
Pharmaron is proud to partner with organizations shaping the healthcare industry’s future. We know that every project we complete helps our partners move one step closer to their goals. These goals impact millions, meaning new life-saving medicines are being discovered.
On April 1, IFM Therapeutics announced a deal where Novartis acquires their subsidiary, IFM Tre’s portfolio of NLPR3 antagonists, which consists of one clinical and two pre-clinical programs.
IFM has been a partner with Pharmaron since 2015. During this period, our teams have provided a broad range of services, including medicinal & process chemistry, DMPK, in vitro biology, and GMP manufacturing.
Learn more about our small molecule services
